Circular 44: REVISIONS TO THE ANTI-DOPING SINGAPORE (ADS) THERAPEUTIC USE EXEMPTION (TUE) POLICY
The ADS TUE Policy has been revised to include changes to the 2017 Prohibited List. The key revisions to the ADS TUE Policy is to Section 4 (Procedure for Asthma Treated with Beta-2 Agonists) on the refinements and guidelines for the thresholds of permitted Beta-2 Agonists for treatment of asthma.